Tango Therapeutics to Present Updated Vopimetostat Combination Trial Data at ESMO 2026
Tango Therapeutics will present updated Phase 1/2 vopimetostat combination data at the ESMO Congress in Madrid on Oct. 25, 2026. The study evaluates vopimetostat with daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant metastatic pancreatic cancer or non-small cell lung cancer. A pancreatic cancer-focused investor webcast is scheduled for Oct. 23 at 7:30 a.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202610160700PRIMZONEFULLFEED9846983) on October 16, 2026, and is solely responsible for the information contained therein. (C)
Tango Therapeutics will present updated Phase 1/2 vopimetostat combination data at the ESMO Congress in Madrid on Oct. 25, 2026. The study evaluates vopimetostat with daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant metastatic pancreatic cancer or non-small cell lung cancer. A pancreatic cancer-focused investor webcast is scheduled for Oct.
23 at 7:30 a.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
Tango Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202610160700PRIMZONEFULLFEED9846983) on October 16, 2026, and is solely responsible for the information contained therein. (C)